Top Cited Articles (Published 2021 – 2022)
Acceptance rate:
23%
Impact Factor (JCR):
10.9
IF rank (Oncology):
29/241
IF rank (Immunology):
18/161
Citescore:
16.8
Total content views:
1.12 million
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events
Targeting immunogenic cancer cell death by photodynamic therapy: past, present and future
Safety and antitumor activity of dostarlimab in patients with advanced or recurrent DNA mismatch repair deficient/microsatellite instability-high (dMMR/MSI-H) or proficient/stable (MMRp/MSS) endometrial cancer: interim results from GARNET - a phase I, single-arm study
Neoadjuvant programmed cell death 1 blockade combined with chemotherapy for resectable esophageal squamous cell carcinoma
STING agonist loaded lipid nanoparticles overcome anti-PD-1 resistance in melanoma lung metastasis via NK cell activation
Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancer
Optimizing therapeutic outcomes of immune checkpoint blockade by a microbial tryptophan metabolite
Acute kidney injury in patients treated with immune checkpoint inhibitors
Gut microbiome is associated with the clinical response to anti-PD-1 based immunotherapy in hepatobiliary cancers
Multicenter, single-arm, phase II trial of camrelizumab and chemotherapy as neoadjuvant treatment for locally advanced esophageal squamous cell carcinoma
Mechanisms of regulatory T cell infiltration in tumors: implications for innovative immune precision therapies
Extracellular HMGB1 blockade inhibits tumor growth through profoundly remodeling immune microenvironment and enhances checkpoint inhibitor-based immunotherapy
Differential influence of antibiotic therapy and other medications on oncological outcomes of patients with non-small cell lung cancer treated with first-line pembrolizumab versus cytotoxic chemotherapy
Tumor-associated macrophages: potential therapeutic strategies and future prospects in cancer
Adoptive cellular therapy in solid tumor malignancies: review of the literature and challenges ahead
Consensus disease definitions for neurologic immune-related adverse events of immune checkpoint inhibitors
Off-the-shelf V delta 1 gamma delta T cells engineered with glypican-3 (GPC-3)-specific chimeric antigen receptor (CAR) and soluble IL-15 display robust antitumor efficacy against hepatocellular carcinoma
COVID-19 in immunocompromised populations: implications for prognosis and repurposing of immunotherapies
Regorafenib enhances antitumor immunity via inhibition of p38 kinase/Creb1/Klf4 axis in tumor-associated macrophages
Clinical activity of durvalumab for patients with advanced mismatch repair-deficient and repair-proficient endometrial cancer. A nonrandomized phase 2 clinical trial